MBRXMoleculin BiotechMBRX info
$2.38info1.71%24h
Global rank22519
Market cap$79.52M
Change 7d-5.56%
YTD Performance177.39%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Moleculin Biotech (MBRX) Stock Overview

    Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

    MBRX Stock Information

    Symbol
    MBRX
    Address
    5300 Memorial DriveHouston, TX 77007United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.moleculin.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    713 300 5160

    Moleculin Biotech (MBRX) Price Chart

    -
    Value:-

    Moleculin Biotech Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $2.38
    N/A
    Market Cap
    $79.52M
    N/A
    Shares Outstanding
    33.41M
    N/A
    Employees
    15.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org